关键词: AMD, Age-related macular degeneration BDNF, Brain derived neurotrophic factor CNTF, Ciliary neurotrophic factor GDNF, Glial‐derived neurotrophic factor Glaucoma IOP, Intraocular pressure LoGTS, Low-Pressure Glaucoma Treatment Study MRI, Magnetic resonance imaging MSCs, Mesenchymal stem cells NGF, Nerve growth factor NTG, Normal tension glaucoma OCTA, Optical coherence tomography angiography PBM, hotobiomodulation PDGF, Platelet derived growth factor POAG, Primary open angle glaucoma RGCs, Retinal ganglion cells TNF-α, Tumor necrosis factor- α bFGF, Basic fibroblast growth factor gene therapy intracranial pressure intraocular pressure neuroprotection ocular blood flow oxidative stress retinal ganglion cells stem cell therapy

来  源:   DOI:10.1016/j.survophthal.2021.12.003

Abstract:
Glaucoma, a progressive optic neuropathy characterized by retinal ganglion cell degeneration and visual field loss, is the leading cause of irreversible blindness worldwide. Intraocular pressure (IOP) is presently the only modifiable risk factor demonstrated to slow or halt disease progression; however, glaucomatous damage persists in almost 50% of patients despite significant IOP reduction. Many studies have investigated the non-IOP-related risk factors that contribute to glaucoma progression as well as interventions that can prevent or delay glaucomatous neurodegeneration and preserve vision throughout life, independently of IOP. A vast number of experimental studies have reported effective neuroprotection in glaucoma, and clinical studies are ongoing attempting to provide strong evidence of effectiveness of these interventions. In this review, we look into the current understanding of the pathophysiology of glaucoma and explore the recent advances in non-IOP related strategies for neuroprotection and neuroregeneration in glaucoma.
摘要:
暂无翻译
公众号